MacroGenics, Inc. (NASDAQ:MGNX) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 04:30 pm ET
to enter clinical testing this year. We recently received FDA clearance of the Investigational New Drug, or IND, application for IMGC936, an ADC targeting ADAM9 that is being advanced under a co-development agreement with ImmunoGen. Under this 50-50 collaboration, ImmunoGen will be leading clinical development, and they expect to initiate a Phase I dose escalation study in patients with select advanced solid tumors in the fourth quarter of 2020.
For background, ADAM9, a disintegrin and metalloproteinase domain containing protein nine is a cell surface antigen that is overexpressed in very solid tumor types and has been shown to correlate with core prognosis in several cancers. This regulation of ADAM9 has been implicated in tumor progression and metastasis as well as pathological neovascularization. Anti-ADAM9 antibodies are efficiently internalized and degraded by ADAM9 expressing tumors, making it an attractive ADC target for delivering a cytotoxic payload.
IMGC936 is comprised of a humanized antibody engineered by MacroGenics, conjugated in a site-specific manner to a DM21, a next-generation linker/payload designed by ImmunoGen. This molecule combines a maytansinoid microtubule-disrupting payload with a peptide linker that is designed to convey greater stability and bystander activity than other DM platforms. The drug antibody ratio, or DAR, is 2.
As you can see, we continue to build momentum and advance our pipeline of innovative product candidates. We would now be happy to open the call for questions. Operator?